View All Open Clinical Trials
Use this page to search all trials that are open to enrollment for adult and pediatric patients. For more information on clinical trials at Sanford Health, call or email Bemidji Clinical Research at (218) 333-4869, Bismarck Clinical Research at (701) 323-5760, Fargo at (701) 234-2383; and Sioux Falls Clinical Research at (605) 328-1368. You can also learn more by visiting clinicaltrials.gov, which is a comprehensive national registry of all clinical trials.
Blinded Reference Set For Multicancer Early Detection Blood Tests
Understanding the Impact of Drug Shortages on Oncology Care Delivery
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or more Brain Metastases
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Breast Cancer Bone Metastasis Testbeds
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer and T3N0 Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices On Incorporating Chemoprevention into Care (MiCHOICE)
Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Endocrine Therapy-Induced Alopecia Natural History Evaluation
Prospective cohort study embedded into integrated health care systems in the US to study cancer etiology, prevention, and early detection (Study Documentation avail-see Clinical Research)
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial
Regulation of the mTOR pathway in colon cancer pathology
AKT/mTOR Pathway in Obesity and Colorectal CancEr (CRC): Molecular IntercONnections and Potential Clinical Applications
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
CORRECT-MRD II: Second ColoRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Prostate Cancer Bone Metastasis Testbed for Regenerative Bone Therapies for Bone Metastasis
A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Sanford Genomic Consortium Collaborative Project-Immune Profiling in Primary Immunodeficiency
COMPASS: Community Oncology use of Molecular Profiling to Personalize the Approach to Specialized cancer treatment at Sanford
Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature ® Status” [GOG-3082]
Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum based chemotherapy plus bevacizumab
A Randomized, Phase 2 Study of Pembrolizumab and Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High Grade Serous Ovarian Cancer
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
NRG-GY026: A PH II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-OYSK (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Role of tumor microenvironment on tumor progression, drug resistance and immune escape
Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH HIGH-DOSE CISPLATIN (100 MG/M2) EVERY THREE WEEKS VERSUS RADIATION WITH LOW-DOSE WEEKLY CISPLATIN (40 MG/M2) FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
SH Dr. Spanos Chemokine
Implementation and Effectiveness Trial of HN-STAR
The National Myelodysplastic Syndromes (MDS) Study
A Phase 2 Study to Evaluate the Safety and Efficacy of MK-1026 in Participants with Hematologic Malignancies
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 in Participants with Selected Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Humanitarian Use Device: Optune Lua
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or Single-Agent Maintenance
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation
Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy
A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors
A pilot study to evaluate circulating tumor cells (CTC) in patients with locally advanced and metastatic solid tumors
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Select Solid Tumors
CIBMTR Research Database
Umbrella Long-Term Follow-Up Protocol
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
COG ACCL2031 A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Study of Selumetinib (NSC# 74827, IND#77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressiv Low-Grad Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
COG ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Tool for monitoring Chemotherapy Induced Peripheral Neuropathy (CIPN)
Lipoprotein(a) and Aortic Valve Calcification Risk in Children: Assessing the risk of Aortic Valve Calcification in Children with Elevated Lipoprotein (a)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Key Adverse Events after Childhood Cancer
Rapid Whole Genome Sequencing (rWGS): Rapid Genomic Sequencing for Acutely Ill Patients and the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
ATHN 10: Leveraging the ATHNdataset to Document the State of Rare Coagulation Disorders in the United States
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphonma.
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
OBSERVATIONAL STUDY OF PEDIATRIC RHEUMATIC DISEASES THE CARRA REGISTRY
Renal Tumors Classification, Biology, and Banking Study
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
ARDS in Children and ECMO initiation strategies impact on Neuro-Development (ASCEND)
AGCT1532, Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamine (VINO-AC) plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-Cpo) vs Vincristine, Dactinomycin and Cyclophosphamine (VAC) plus VINO-Cpo Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
safety follow up study with the main objective to determine long-term safety and durability response after treatment with teplizumab
SH Dr. Griffin PLEDGE Monitoring
Sanford Population Level Estimate of Type 1 Diabetes Risk GEnes in Children
The Experience of Internationally Educated Nurses Transition to Nursing Practice at a Rural Healthcare System
Limited access protocol for the use of oral cisapride in the treatment of pediatric patients with refractory gastroesophageal reflux disease and other gastrointestinal motility disorders.
Effect of Vagus Nerve Preservation During Gastric Bypass on Gastrin Level and Marginal Ulcer Formation
Validation of CardioMEMS HF System Cardiac Output Algorithm (VICTOR) IDE
PK Papyrus Covered Coronary Stent System is a Humanitarian Use Device approved under a Humanitarian Device Exemption
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-Vitamin K Antagonist Oral Anticoagulants
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Multiple Patient Program for Lamprene (clofazimine) forthe treatment of Non-Tuberculous
A Safer Effective Method to Control the Serum Bilirubin of Extremely Premature Infants?
Milrinone in Congenital Diaphragmatic Hernia
SONPM National Registry for Perinatal COVID -19 Infections
All Birth Cohort (ABC) Study
Randomized Placebo-controlled Trial to Shorten Pharmacologic Treatment of Newborns with Neonatal Opioid Withdrawal Syndrome (NOWS)
FOLLOW-UP STUDY Follow-up Visit of High Risk Infants
Survey of Morbidity and Mortality among high risk preterm infants
Study of Attitudes and Factors Effecting Preterm Infant Care Practices
Urinary uromodulin as a biomarker for TAL and distal nephron adaptation in patients undergoing diuretics treatment
A Prospective Registry Study in a Global Huntingtons Disease Cohort A CHDI Foundation Project
REal-World Analyses of Stroke – Thrombus Occlusion REtrieval (RESTORE) previously SOFAST
Parallel trial of the two treatment options, Intensive Medical Management vs. CEA (carotid enterectomy) arm only, Intensive Medical Management vs. CAS (carotid artery stenting) only, or both arms depending on your capability.
Defining clinically significant fatigue in Parkinson’s disease
Transcranial direct current stimulation (tDCS) to improve cognitive function and cognitive fatigue in Parkinson’s patient mild cognitive impairment (MCI)
SH UND Pathophysiology of orthostatic hypotension in Parkinson’s Disease
Attention and Memory in Parkinson's Disease
Strahm-Maternal Stress and Blood Sugar Metabolism During Pregnancy
Anna Strahm-Midwest Birth Outcomes and Indigenous American Pregnancy
Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)
Minimally Invasive Deformity Correction (MID-C) System – H170001
MILES Extension Study: Two and Three Year Follow Up in subjects who previously received Mesenchymal Stem Cells or Corticosteroid Injection as part of the MILES randomized clinical trial
The Effects of Combination Therapy of Opioids versus Non-Opioids on Postoperative Pain Management after Knee Arthroscopic Surgery: A Prospective Randomized Controlled Study
SH Dr. Thayne Munce USD Neuroimaging for MMA Fighters
Trauma and mild TBI in a pediatric population: A pilot longitudinal descriptive study assessing post-concussive symptoms, functional and quality of life outcomes.
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra®/Beriplex®]) to Improve Survival in Patients with Traumatic Injury and Confirmed or Suspected Acute Major Bleeding Predicted to Receive a Large Volume Blood Product Transfusion
A Prospective Study of Emergency Department / Urgent Care Revisit Rates among Discharged Rib Fracture Patients with Involvement of Community Paramedics
Product Surveillance Registry (PSR) Platform Base Protocol
A Double Blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Persistent or Recurrent Stress Urinary Incontinence Following Surgical Treatment
Interstitial Cystitis / Bladder Pain
Reviewing an Alternative Botox Injection Paradigm
Safety Assessment of MRI Imaging of All Body Parts in Patients with Implanted InterStim Therapy
Prospective cohort study embedded into integrated health care systems in the US to study cancer etiology, prevention, and early detection (Study Documentation avail-see Clinical Research)
Cystic Fibrosis Patient Registry
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Impact of a PGx Clinic visit on PGx Guided Medication Outcomes
Sanford Childrens Metabolomics Collaboration with Stanford
Patient Satisfaction with a Pharmacogenetic Services
The Sanford Health BioBank
SH Sanford Polygenic Risk ScOre ReTurn of REsults for Coronary Artery Disease
Genetic Epidemiologic Services for Establishing Genetic Risk Scores (GRSs) for the Sanford Imagenetics Program.
Sanford Polygenic Risk Score in Cardiology [Working Title]
The Sanford Neurodevelopmental Services Registry
an observational study of pharmacogenomic testing in pediatric patients with depression and/or anxiety